Prothymosin α fragmentation in apoptosis  by Evstafieva, Alexandra G. et al.
Prothymosin K fragmentation in apoptosis
Alexandra G. Evsta¢evaa, George A. Belova;b, Markus Kalkumc, Nina V. Chichkovaa,
Alexey A. Bogdanova, Vadim I. Agola;b, Andrey B. Vartapetiana;*
aBelozersky Institute of Physico-Chemical Biology and Center of Molecular Medicine, Moscow State University, Moscow 119899, Russia
bChumakov Institute of Poliomyelitis and Viral Encephalitides, Russian Academy of Medical Sciences, Moscow Region 142782, Russia
cMax-Planck Institut fu«r Molekulare Genetik, D-14195 Berlin, Germany
Received 22 December 1999
Edited by Vladimir Skulachev
Abstract We observed fragmentation of an essential prolifera-
tion-related human nuclear protein prothymosin K in the course
of apoptosis induced by various stimuli. Prothymosin K cleavage
occurred at the DDVD99 motif. In vitro, prothymosin K could be
cleaved at D99 by caspase-3 and -7. Caspase hydrolysis disrupted
the nuclear localization signal of prothymosin K and abrogated
the ability of the truncated protein to accumulate inside the
nucleus. Prothymosin K fragmentation may therefore be
proposed to disable intranuclear proliferation-related function
of prothymosin K in two ways: by cleaving off a short peptide
containing important determinants, and by preventing active
nuclear uptake of the truncated protein.
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1. Introduction
Prothymosin K (ProTK) is a small (109 amino acid residue)
highly acidic nuclear protein found in virtually all mammalian
tissues, the most abundant source being the thymus [1^3].
Several lines of evidence support the notion that ProTK is
an essential protein related to cell proliferation. ProTK is an
abundant protein in proliferating cells and, in particular, in
cancer cells [4]. A low ProTK mRNA level observed in quies-
cent cells is increased markedly upon growth stimulation with
mitogens or serum [5]. ProTK gene expression is up-regulated
by c-Myc [6] due to the presence of a functional E-box in the
ProTK gene [7]. Overexpression of ProTK in NIH3T3 and
HL-60 cells was shown to stimulate cell division due to short-
ening of the G1 phase [8,9], suggesting the involvement of
ProTK in the G1/S transition or the S phase of the cell cycle.
Furthermore, overexpression of ProTK resulted in inhibition
of cell di¡erentiation [9]. Finally, inhibition of ProTK synthe-
sis by treatment with ProTK antisense oligonucleotides pre-
vented cell division in a synchronized population of human
myeloma cells [10] and induced apoptosis in HL-60 cells [11].
The mechanism of ProTK action is unknown. Subcellular
localization pointed to the nucleus as a compartment for ac-
cumulation and most probably functioning of ProTK [12^15].
The active nuclear uptake of ProTK is mediated by a bipartite
nuclear localization signal (NLS) [16]. Here, we present evi-
dence that ProTK is subjected to caspase-mediated fragmen-
tation in the course of apoptosis. The carboxy terminal cas-
pase cleavage disrupting the NLS of the protein results in a
truncated ProTK derivative which fails to accumulate inside
the nucleus.
2. Materials and methods
2.1. Plasmid constructions
pHT15A containing the protein-coding region of the human wild-
type ProTK cDNA was derived from pHT15 [17] by eliminating the
G(75)V mutation by site-directed mutagenesis. The D(99)N mutation
was introduced in ProTK sequence by PCR on pHP12 [17] with the
mutagenic primer (5P-GATGTCAATACCAAGAAGCAG-3P) to pro-
duce pHP-caspN. For constructing pKT1 encoding, in successive or-
der, a His-tag, a thrombin cleavage site, a protein kinase recognition
site, and human ProTK as a single fusion protein, the ProTK-encoding
DNA fragment from pHT15A was inserted into pET33b(+) vector
(Novagen) between the ¢lled-in NheI site and EcoRI site. To obtain
pEGFP-ProTK, BamHI-EcoRI fragment from pHT15A was inserted
into BglII-EcoRI sites of pEGFP-C2 vector (Clontech). cDNA encod-
ing the ProTK (1^99) fragment was obtained in pHT15A by convert-
ing the threonine-100 ACC codon into the TAG termination codon.
The resultant cDNA was inserted in pEGFP-C2 in analogous fashion,
producing the pEGFP-ProTK(1^99) plasmid. The structure of resul-
tant constructs was con¢rmed by sequencing.
2.2. Cell cultures
A subline of HeLa-S3 cells designated HeLa-B [18] cultivated in
DMEM supplemented with 10% of bovine serum was used. Apoptosis
was induced in 1 day old cell cultures grown at 2U107 cells per roller
bottle by incubating the cells in DMEM containing staurosporine
(1 WM, Sigma) for 2 or 4 h; cycloheximide (100 Wg/ml) for 3.5 h;
or cisplatin (20 Wg/ml, provided by P. Cheltsov, Institute of General
and Inorganic Chemistry, Moscow, Russia) for 15 h. In the latter
case, the medium contained 2% bovine serum. In addition, apoptosis
was induced by abortive poliovirus type 1 Mahoney strain infection,
with cycloheximide (10 Wg/ml) added at 1.45 h postinfection [18,19].
Incubation was for 6.45 h at 37‡C.
Upon incubation, small aliquots of the cells were suspended in PBS
and stained with 5 Wg/ml of £uorescent permeable nuclear dye
Hoechst-33342 (Sigma). The percentage of apoptotic cells was esti-
mated observing nuclear morphology with epi£uorescent Leica
DMLS microscope equipped with ¢lter cube A. The bulk of the cells,
including those from supernatant and the ones still attached to the
bottle, were collected and stored at 380‡C for subsequent isolation of
ProTK.
Transfection of the HeLa-B cells with 10 Wg of pEGFP-ProTK,
pEGFP-ProTK(1^99), and pEGFP-C2 (Clontech) was performed by
using a modi¢cation of the calcium phosphate precipitation method,
as described at http://www.sciencexchange.com/sxprotocols/molbiol/
phoenx.htm. Two days after transfection localization of the EGFP-
ProTK fusion proteins was examined with the epi£uorescent micro-
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scope equipped with ¢lter cube I3. In parallel, lysates of 106 cells from
each culture were obtained by boiling in the Laemmli sample bu¡er
followed by brief sonication and subjected to 12% SDS^PAGE and
immunoblotting using a⁄nity-puri¢ed rabbit anti-GFP antibodies.
Detection of EGFP-containing bands was performed by using donkey
anti-rabbit Ig conjugated with horseradish peroxidase and ECL West-
ern blotting detection reagents (Amersham Pharmacia).
2.3. Isolation of ProTK and its derivative from HeLa cells
ProTK and its caspase cleavage product were isolated from 5U107
HeLa-B cells by the phenol extraction procedure essentially as de-
scribed [17]. The ¢nal high salt/phenol extraction step was applied
to the staurosporine- and cisplatin-induced probes only to eliminate
the bulk of cellular RNAs from the ProTK preparation. The samples
were subjected to 8% PAGE/7 M urea (without SDS), and the ProTK
bands were visualized by methylene blue staining as described [17].
For MALDI-MS analysis, the band containing ProTK fragment was
cut out basing on its relative electrophoretic mobility without staining
the gel. Elution of the ProTK fragment from the gel was performed by
addition of 300 Wl GES (0.5 M ammonium acetate/1 mM EDTA/0.1%
SDS) to excised gel pieces with subsequent vigorous shaking at room
temperature overnight. The protein was precipitated with 3 volumes
of ethanol, dissolved in water, and loaded on a 50 Wl DE-52 column
equilibrated with a bu¡er containing 20 mM Tris^HCl, pH 7.5/100
mM NaCl. After extensive washing, ProTK fragment was eluted with
the bu¡er containing 0.5 M NaCl followed by ethanol precipitation,
and was ¢nally dissolved in water.
2.4. MALDI-MS analysis of the ProTK cleavage product
Matrix assisted laser desorption/ionization mass spectrometric
(MALDI-MS) analysis was performed on a Re£ex-II instrument
(Bruker Daltonik, Bremen, Germany) in linear and in re£ector
mode. MALDI-MS samples were prepared applying the dried drop
method on stainless steel targets pre-covered with thin matrix ¢lms.
0.6 Wl of puri¢ed ProTK fragment (V0.3 ng) were mixed with 0.6 Wl
of saturated sinapinic acid in acetonitrile/0.1% TFA (2:1 v/v) as ma-
trix on the ‘scout-26’ MALDI-MS target. The dried sample spots were
washed by depositing V4 Wl of ice-cold 5% TFA on top of them
followed by rapid removal of the wash solution. Horse heart cyto-
chrome c, human ubiquitin and bovine insulin were used as external
mass standards. Isolated ProTK fragment was also submitted to tryp-
tic digestion using 100 ng sequencing grade modi¢ed trypsin (Boehr-
inger Mannheim). Mixture of peptides was puri¢ed on C-18 ZipTip
micro columns (Millipore, Bedford, MA, USA) and analyzed by
MALDI-MS in the presence of K-cyano-4-hydroxy-cinnamic acid as
matrix.
2.5. Production and puri¢cation of recombinant proteins
The recombinant human wild-type ProTK and ProTK D(99)N mu-
tant were isolated from Escherichia coli BL21(DE3)/pHP12 and /pHP-
caspN cells as described [17] and additionally puri¢ed by DE-52 cel-
lulose column chromatography. To obtain [32P]-end labelled ProTK,
the recombinant ProTK derivative was isolated from the lysate of E.
coli BL21(DE3)/pKT1 cells by means of Ni-NTA agarose (Qiagen)
a⁄nity chromatography. The 1 Wg ProTK aliquot was subjected to
radiolabelling by incubating with 100 WCi [Q-32P]ATP (5000 Ci/mmol)
and 1 U protein kinase A (catalytic subunit, Sigma). After ethanol
precipitation, the labelled ProTK derivative was treated with 0.1 U
thrombin in the thrombin cleavage bu¡er (Novagen) to eliminate the
His-tag. The hydrolysate was fractionated by 8% PAGE/7 M urea, the
labelled ProTK was eluted from the gel, ethanol precipitated and dis-
solved in water. The speci¢c radioactivity of [32P]-labelled ProTK was
107 cpm/Wg.
2.6. In vitro caspase cleavage assays
Human caspase-3 and caspase-7 and -8 were kindly provided by
Y. Lazebnik (Cold Spring Harbor Laboratory, Cold Spring Harbor,
NY, USA) and G. Salvesen (The Burnham Institute, La Jolla, CA,
USA), respectively. Caspases were preincubated in 25^250 ng aliquots
with or without 30 WM zVAD-fmk or 10 WM zDEVD-fmk in 10 Wl
of a bu¡er containing 50 mM HEPES, pH 7.5/100 mM NaCl/
10% glycerol/10 mM DTT at room temperature for 15 min. The re-
actions were initiated by the addition of 3 Wg unlabelled ProTK or
10 000 cpm [32P]-labelled ProTK in 2^5 Wl of the same bu¡er. After
incubation at 37‡C for 2 h, the samples were analyzed by 8% PAGE/
7 M urea.
3. Results
3.1. ProTK fragmentation in apoptotic cells
Amino acid motifs D-x-x-D conforming to a caspase rec-
ognition site are present close to the carboxy terminus of the
human ProTK molecule (Fig. 1A). We aimed to determine
whether ProTK fragmentation occurs in apoptotic cells.
The integrity of ProTK in control non-infected and polio-
virus-infected HeLa cells (non-apoptotic) was compared with
that of ProTK isolated from cells triggered to undergo apop-
tosis by various stimuli : treatment with cycloheximide, cispla-
tin, staurosporine, and abortive poliovirus infection. In the
latter case, a combination of poliovirus infection with cyclo-
Fig. 1. A: Diagram showing the putative caspase recognition motifs
in human ProTK positioned within the spacer region of the bipartite
NLS. B: Typical apoptotic morphology of nuclei of HeLa cells
treated with staurosporine for 4 h. The cells were stained with
Hoechst-33342 and examined by £uorescence microscopy. C: ProTK
fragmentation in apoptotic HeLa cells. ProTK was partially puri¢ed
from HeLa cells induced to undergo apoptosis by various stimuli
and from control (non-apoptotic) untreated and poliovirus-infected
HeLa cells. The samples were resolved by electrophoresis in an 8%
polyacrylamide/7 M urea gel and visualized by methylene blue stain-
ing. Lane M, recombinant full-length ProTK and an arti¢cial dele-
tion mutant lacking nine carboxy terminal residues [21] used as
markers. The percentage of apoptotic cells in cultures is indicated at
the bottom of each lane. CHX, cycloheximide.
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heximide treatment at low concentration of the drug was em-
ployed, neither of which alone elicited an appreciable apop-
totic response (Agol et al., in preparation). The cells induced
to undergo programmed death displayed characteristic mor-
phological features of apoptosis, such as chromatin condensa-
tion, fragmentation of the nucleus (Fig. 1B), and cytoplasmic
membrane blebbing. ProTK and its putative fragments were
isolated from the apoptotic and control cells by a phenol
extraction procedure [17,20] which exploits a unique property
of highly acidic and hydrophilic ProTK to retain in the aque-
ous phase, and fractionated by PAGE. As evident from Fig.
1C, ProTK fragmentation occurred in all of the cell cultures
induced to undergo apoptosis and in none of the control cell
cultures. Electrophoretic mobility of the truncated ProTK was
consistent with the predicted cleavage of a short fragment
from the protein molecule. The extent of ProTK fragmenta-
tion was roughly proportional to the amount of cells under-
going apoptosis. ProTK cleavage has already become evident
at 2 h post induction of apoptosis (Fig. 1C) suggesting that
ProTK fragmentation is an early event.
To obtain an unequivocal proof that the shifted band ob-
served in apoptotic cell samples corresponds to a ProTK de-
rivative and to determine the site of proteolytic cleavage,
MALDI-MS analysis of the truncated protein and its tryptic
peptides was performed using the gel-puri¢ed material iso-
lated from HeLa cells subjected to cisplatin and to polio-
virus+cycloheximide-induced apoptosis. The m/z values of
the singly and double charged molecule at 10 796.7 and
5398.9, respectively, corresponded to the calculated values
for the ProTK(1^99) fragment (Fig. 2A). Furthermore, this
Fig. 2. MALDI-MS identi¢cation of the ProTK(1^99) fragment gen-
erated in apoptotic cells. A: Molecular mass determination of the
entire fragment. Mass over charge ratios (m/z) of the singly
[M+H] and doubly [M+2H]2 charged ions comply with the calcu-
lated values. The calculated m/z of the singly charged ProTK(1^99)
fragment corresponds to 10 796.5. B: Tryptic peptide mapping anal-
ysis of the same ProTK fragment.
C
Fig. 3. ProTK fragmentation in vitro. A: The in vitro treatment of
recombinant human ProTK (3 Wg per lane) with caspase-3 (180 ng),
-7 (75 ng), and -8 (200 ng). B: Cleavage of the [32P]-amino termi-
nally labelled ProTK (10 000 cpm per lane) with caspase-3 (lane 5,
25 ng, and lanes 6, 7, 250 ng) and -7 (75 ng). C: The D(99)N muta-
tion in ProTK abolishes its fragmentation with caspase-3 and -7.
Wild-type (wt) ProTK and the ProTK mutant D(99)N (3 Wg per
lane) were treated with caspase-3 (50 ng) and -7 (40 ng). The sam-
ples were fractionated in an 8% polyacrylamide/7 M urea gel and
visualized by methylene blue staining (A and C) or by autoradiogra-
phy (B).
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assignment was con¢rmed by MALDI-MS tryptic peptide
mapping analysis of the same fragment, comprising 95% cov-
erage of its sequence including the acetylated amino terminus
and the new carboxy terminus generated through the cleavage
(Fig. 2B). Thus proteolytic cleavage occurred at the aspartic
acid residue-99 in the protein sequence DDVD99.
3.2. Caspase-3 and -7 cleave ProTK in vitro
Recombinant human ProTK was treated with caspase-3, -7,
or -8 and fractionated by PAGE. Both caspase-3 and -7 pro-
duced a truncated form of ProTK with an electrophoretic
mobility similar to that of the ProTK fragment observed in
the in vivo samples (Fig. 3A), while treatment with caspase-8
was without any e¡ect. Both a broad spectrum caspase inhib-
itor zVAD-fmk and the speci¢c caspase group II inhibitor
zDEVD-fmk abolished ProTK fragmentation by caspase-3
and -7 (Fig. 3 and data not shown).
An alternative substrate employed for the in vitro ProTK
cleavage was represented by a [32P]-end labelled ProTK deriv-
ative carrying a protein kinase A recognition motif at its ami-
no terminus. This ProTK substrate provided an increased sen-
sitivity for the cleavage assay and, besides, permitted
discrimination between the carboxy and amino terminal cleav-
age sites in the in vitro reaction. Treatment of [32P]ProTK
with caspase-3 and -7 produced a characteristic band with
an electrophoretic mobility similar to that of the ProTK(1^
99) derivative (Fig. 3B). Preservation of the [32P]-label in
this shifted band indicated that the carboxy terminal cleavage
has occurred. In this sensitive assay, however, the increased
amount of caspase-3 produced a second minor radiolabelled
band (Fig. 3B, lane 6). The lower electrophoretic mobility of
this newly observed band was most probably due to a de-
creased negative charge of a short ProTK fragment. Although
the nature of this material was not further characterized, its
appearance may indicate the existence of an additional minor
caspase-3 cleavage site(s) in the amino terminal region of
ProTK molecule, at least in vitro.
ProTK fragments generated by caspase-3 and -7 from the
recombinant ProTK lacking arti¢cially added sequences (Fig.
3A, lanes 2 and 4), as well as tryptic peptides thereof, were
subjected to MALDI-MS analysis. The data obtained con-
¢rmed that in both cases the cleavage at D99 has occurred
(data not shown). To further characterize the caspase cleav-
age, the ProTK D(99)N mutant was constructed. The D(99)N
mutation impaired the caspase-3-, as well as the caspase-7-
mediated ProTK cleavage (Fig. 3C). Thus both caspase-3
and -7 utilize the same DDVD99 motif for ProTK processing.
3.3. ProTK cleavage product fails to accumulate inside the
nucleus
ProTK is a nuclear protein. Nuclear targeting of ProTK is
provided by a bipartite NLS consisting of the two short
stretches of basic amino acids separated by a spacer region
[16]. The identi¢ed cleavage site is positioned inside the spacer
region of this NLS (Fig. 1A). Therefore, proteolytic cleavage
occurring in apoptotic cells generating ProTK(1^99) fragment
should lead to elimination of the second basic part of the
NLS, which was shown previously to be crucial for the accu-
mulation of ProTK in the nucleus [16].
To compare the subcellular localization of the ProTK(1^99)
fragment with that of full-length ProTK, HeLa cells were
transfected with plasmids encoding either wild-type ProTK
or arti¢cially constructed ProTK(1^99) fragment mimicking
the proteolytic cleavage product, fused to the carboxy termi-
nus of GFP. Fluorescence microscopy of the transfected cells
revealed that while the wild-type ProTK was exclusively nu-
clear (Fig. 4A), the ProTK(1^99) fragment lacked the ability
to preferentially accumulate inside the nucleus and appeared
to be evenly distributed within the cell (Fig. 4B). Western blot
analysis of the GFP-ProTK and GFP-ProTK(1^99) from cell
lysates using anti-GFP antibodies con¢rmed that no degrada-
tion of the fusion proteins occurred (Fig. 4C). Thus lack of
active nuclear uptake is a property of the ProTK(1^99) frag-
ment.
Fig. 4. Subcellular localization of the full-length ProTK (A) and the
ProTK(1^99) fragment (B) fused to EGFP. HeLa cells were trans-
fected with the expression constructs and examined by £uorescence
microscopy. C: Lysates of HeLa cells producing EGFP, EGFP-
ProTK and EGFP-ProTK(1^99) were subjected to 12% SDS^PAGE
and immunoblotting with anti-GFP antibodies.
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4. Discussion
Our studies add ProTK, an essential nuclear protein in-
volved in cell proliferation, to the expanding yet limited list
of the proteins subjected to caspase-mediated degradation in
the course of programmed cell death. ProTK cleavage occurs
in cells triggered to undergo apoptosis by a variety of cell
death inducers and may therefore represent a general feature
of apoptotic cell. Caspase fragmentation of ProTK appears to
be an early event detectable as early as 2 h post induction of
apoptosis. ProTK cleavage occurred close to the carboxy ter-
minus of ProTK at DDVD99. ProTK fragmentation at D99
was readily observed both in vivo and in vitro. In vitro, cas-
pase-3 and -7, but not caspase-8, could cleave ProTK at D99,
and the D(99)N mutation abrogated this cleavage. Caspase-7
is activated independent of caspase-3 [22], each inducing dis-
tinct downstream intracellular events. It would be instructive
to learn which one of these two enzymes, or both, accomplish
the cleavage in vivo.
ProTK fragmentation in apoptosis is likely to impair intra-
nuclear proliferation-related functioning of ProTK through
removal of an important determinant within the cleaved-o¡
fragment, as exempli¢ed by the T(105)A loss-of-function mu-
tation [16], as well as through abrogation of the active nuclear
import of ProTK. Together with a recent observation indicat-
ing that treatment of the cell with ProTK antisense oligonu-
cleotides is able to induce apoptosis [11], our results suggest
that ProTK elimination either naturally (by caspase fragmen-
tation) or arti¢cially (by arrest of translation of ProTK
mRNA) may promote switching the cells from proliferation
to apoptosis. Therefore, a high level of ProTK production in
cancer cells may not only maintain their high proliferative
status, but also protect these cells from entering into the apop-
totic pathway.
Thymus is the organ richest in ProTK, and this observation
was commonly associated with the intense thymocyte prolif-
eration. However, thymus appears to be the right place for
apoptotic fragmentation of ProTK as well. Indeed, over 90%
of immature thymocytes die in the thymus by caspase-medi-
ated apoptosis in the course of positive and negative selection
[23,24] and should provide therefore a very signi¢cant source
of thymic ProTK-derived peptide(s). It is of interest to note
that thymosin K1, the amino terminal peptide of ProTK iso-
lated from the thymus, was reported to be externalized by the
cell and activate the cells of the immune system (reviewed in
[25]). ProTK fragmentation and relocalization in an apoptotic
cell may be proposed to be the ¢rst step in converting nuclear
protein into an externalized bioactive peptide. It would be
instructive to learn whether externalization of the product of
caspase fragmentation of ProTK (with or without additional
processing) can occur in apoptotic cells, and whether this
release may have a physiological signi¢cance. Processing of
the precursors of interleukin-1L and -18 by caspase-1 and of
the pro-IL-16 by caspase-3, prerequisite for activation and
secretion of these cytokines [26^28], may provide a precedent
for regulation of this type.
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